Treatment-Resistant Depression: An Update on Diagnosis and Management
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Janicak, Philip G. MD; Dowd, Sheila M. PhDEditor(s): Janicak, Philip G. MD Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“A number of staging methods are published, with the three most frequently used being: • Increased resistance is determined by successive failures of various antidepressants and electroconvulsive therapy (ECT);(9) • Distinguishing across a continuum from nonresponse, treatment resistance, and chronic resistant depressi…”
MethodBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“During level 2, those electing augmentation were randomized to either bupropionSR (mean dose = 268 mg/d) or buspirone (mean dose = 41 mg/d).(31) Although both treatments produced similar remission rates (i.”
BackgroundBeesdo, K., Bittner, A., Pine, D. S., Stein, M. B., Höfler, M., Lieb, R., & Wittchen, H.-U. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.903 · Cited by 731 · cited 1×
“In addition, recent data indicate that comorbid social anxiety disorder may predispose to depression recurrence.(12) Other Factors Three other issues may also contribute to inadequate response in depressed populations.”
BackgroundFrasure-Smith, N., & Lespérance, F. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.4 · Cited by 571
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Depression Screening and Patient Outcomes in Cardiovascular Care: A Systematic Review
Thombs, B. D., de Jonge, P., Coyne, J. C., Whooley, M. A., Frasure-Smith, N., Mitchell, A. J., Zuidersma, M., Eze-Nliam, C., Lima, B. B., Smith, C. G., et al. (2008) · JAMA · doi:10.1001/jama.2008.667 · Cited by 472
Lisanby, S. H., Husain, M. M., Rosenquist, P. B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L. B., Aaronson, S., Daskalakis, Z. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.118 · Cited by 333 · cited 1×
“006).(41) Despite using the most aggressive TMS treatment administration thus far, there were no adverse systemic or neurocognitive effects, seizures, or deaths.”
MethodThase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332 · cited 2×
“A fourth switch option in level 2 was depressionfocused cognitive therapy (CT), which was comparable in efficacy but better tolerated than the medication options.(20) Further, those with an insufficient response to CT could enter level 2A which involved randomization to either venlafaxine ER or bupropion SR.”
MethodResultDunner, D. L., Rush, A. J., Russell, J. M., Burke, M., Woodard, S., Wingard, P., & Allen, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0501 · Cited by 234
Cited by
Duric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304
Eisendrath, S. J., Gillung, E., Delucchi, K. L., Segal, Z. V., Nelson, J. C., McInnes, L. A., Mathalon, D. H., & Feldman, M. D. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442260 · Cited by 187
Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130
Ramasubramanian, V., Mathumathi, S., Rajendhiran, G., Bijulakshmi, P., & Kannan, M. (2022) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_217_20 · Cited by 10
Metadata
- Authors
- Janicak, P. G., & Dowd, S. M.
- Venue
- Psychopharm Review
- Published
- 2009-06
- Volume
- 44
- Issue
- 6
- Pages
- 41-48
- ISSN
- 1936-9255 (ISSN-L)
- OpenAlex
- W2315786034
- Cited by
- 17
- References
- 15
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment-Resistant Depression: An Update on Diagnosis and Management. https://app.cochat.ai/papers/10.1097/01.idt.0000350191.07142.ef
- The paper
- Janicak, P. G., & Dowd, S. M. (2009). Treatment-Resistant Depression: An Update on Diagnosis and Management. Psychopharm Review. https://doi.org/10.1097/01.idt.0000350191.07142.ef
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.